Drugs / HERV-E TCR transduced CD8+/CD34+ enriched T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03354390 | Jul 2018 → Oct 2023 overdue | kidney cancer | National Heart, Lung, and Blood Institute (NHLBI) | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HERV-E TCR transduced CD8+/CD34+ enriched T cells | “followed by an infusion of HERV-E TCR transduced CD8+/CD34+ enriched T cells” NCT03354390 ↗ |
| Known as | HERV-E T cells | “antitumor activity of HERV-E TCR-transduced T cells (HERV-E T cells).” PMID 39266213 ↗ Sep 2024 |
| Action | Deplete | “human ccRCC cells can be selectively recognized and killed by TCR-engineered T cells targeting a HERV-derived antigen.” PMID 39266213 ↗ Sep 2024 |
| Modality | Cell therapy | “infusion of HERV-E TCR transduced CD8+/CD34+ enriched T cells” NCT03354390 ↗ |
| Route | Intravenous | “Get 2 chemotherapy drugs by catheter (thin plastic tube) inserted into a vein in the chest. * Get the changed cells via catheter.” NCT03354390 ↗ |